日本药品市场报告（按处方类型、治疗类别和地区划分，2026-2034 年）

Japan Pharmaceutical Market Report by Prescription Type, Therapeutic Category, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 122 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2025年日本医药市场规模达844亿美元。展望未来， IMARC Group预计到2034年，该市场规模将达到1,049亿美元，2026年至2034年期间的复合年增长率（CAGR）为2.45%。众多治疗方法和创新疗法的出现，以及药物研发投入的不断增加，是推动市场成长的主要因素。

本报告解答的关键问题：

日本医药市场目前表现如何？未来几年又将如何发展？
新冠疫情对日本医药市场产生了哪些影响？
日本药品市场依处方类型分類的组成是怎样的？
日本药品市场依治疗类别分類的组成是怎样的？
日本医药市场价值链包含哪些环节？
日本製药业的关键驱动因素和挑战是什么？
日本医药市场的结构是怎么样的？主要参与者有哪些？
日本医药市场的竞争程度如何？

Japan pharmaceutical market size reached USD 84.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 104.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.45% during 2026-2034. Numerous treatments and innovative therapies and the increasing investments in the R&D activities for developing medicines, are primarily augmenting the market growth.

The pharmaceutical industry represents a confluence of science, innovation, and therapeutic care, dedicated to advancing global health. At its core, this sector is responsible for the research, development, production, and distribution of medications designed to prevent, manage, or cure a plethora of medical conditions and diseases. Spanning from life-saving vaccines to everyday pain relievers, pharmaceuticals play an integral role in enhancing the quality of life and increasing life expectancy. The journey of drug development is a complex and rigorous process, necessitating extensive research, clinical trials, and regulatory approvals to ensure both efficacy and safety for patients. Beyond the tangible medications, the pharmaceutical industry's value also lies in its relentless pursuit of new therapeutic frontiers, breakthrough treatments, and innovations that have the potential to redefine medical paradigms. As health challenges continue to evolve, the importance of this industry, underpinned by its commitment to bettering human health, remains paramount.

Japan Pharmaceutical Market Trends:

Growing investments in biopharmaceuticals and precision medicine

Growing investments in biopharmaceuticals and precision medicines is rapidly transforming the dynamics of the pharmaceutical industry in Japan. Biopharmaceuticals, such as biologics, and biosimilars are gaining more preference due to originality in treatment of chronic diseases, such as cancer or autoimmune diseases. With advancements in genomics and personalized medicine, the focus is shifting towards treatments tailored to individual genetic profiles. As a result, major Japanese drug manufacturers are engaging in joint ventures involving overseas companies and research centers to foster this technology. An enhanced focus on individualized treatments is further extending the range of the pharmaceutical market by offering targeted solutions to previously hard-to-solve diseases.

Aging Population and Rising Healthcare Demand

The rapidly aging population is a key factor propelling growth in the pharmaceutical market. This demographic shift is increasing the overall demand for medications targeting age-related diseases and chronic conditions such as cardiovascular diseases, diabetes, and Alzheimer's. Also, with shifting focus to managing chronic illnesses and improving the quality of life for senior citizens, the demand for effective treatments and medications is growing with the improving healthcare system. Furthermore, pharmaceutical companies are expanding their R&D efforts in geriatric medicines, developing comprehensive drug formulations specifically designed for elderly care. This demographic trend is attracting heavy investments from both local and international firms, contributing to the Japan pharmaceutical market share.

Continual technological advancements in drug development and manufacturing

Ongoing innovations in cutting-edge advancements, such as artificial intelligence (AI), machine learning (ML), and process automation, particularly as they are integrated into both preclinical research and drug manufacturing, are supporting the growth of the market. Data-driven methods in clinical trials and drug safety monitoring are helping pharmaceutical companies bring new therapies to market faster. Wearable devices and digital health tools, including telemedicine are also fostering better drug adherence and more personalized treatment plans. Additionally, innovations in bioprocessing and the use of robotics in pharmaceutical production are improving efficiency, while advanced analytics support better decision-making throughout the drug development lifecycle.

Japan Pharmaceutical Market Segmentation:

Prescription Type Insights:

Prescription Drugs
- Branded
- Generics
OTC Drugs

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pharmaceutical market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan pharmaceutical market?
What is the breakup of the Japan pharmaceutical market on the basis of prescription type?
What is the breakup of the Japan pharmaceutical market on the basis of therapeutic category?
What are the various stages in the value chain of the Japan pharmaceutical market?
What are the key driving factors and challenges in the Japan pharmaceutical?
What is the structure of the Japan pharmaceutical market and who are the key players?
What is the degree of competition in the Japan pharmaceutical market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmaceutical Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pharmaceutical Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Pharmaceutical Market - Breakup by Prescription Type

6.1 Prescription Drugs
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Segmentation
  - 6.1.3.1 Branded
  - 6.1.3.2 Generics
- 6.1.4 Market Forecast (2026-2034)
6.2 OTC Drugs
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)

7 Japan Pharmaceutical Market - Breakup by Therapeutic Category

7.1 Antiallergics
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Blood and Blood Forming Organs
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Cardiovascular System
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Dermatological
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Genito Urinary System
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Respiratory System
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2020-2025)
- 7.6.3 Market Forecast (2026-2034)
7.7 Sensory Organs
- 7.7.1 Overview
- 7.7.2 Historical and Current Market Trends (2020-2025)
- 7.7.3 Market Forecast (2026-2034)
7.8 Others
- 7.8.1 Historical and Current Market Trends (2020-2025)
- 7.8.2 Market Forecast (2026-2034)

8 Japan Pharmaceutical Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Prescription Type
- 8.1.4 Market Breakup by Therapeutic Category
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Prescription Type
- 8.2.4 Market Breakup by Therapeutic Category
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Prescription Type
- 8.3.4 Market Breakup by Therapeutic Category
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Prescription Type
- 8.4.4 Market Breakup by Therapeutic Category
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Prescription Type
- 8.5.4 Market Breakup by Therapeutic Category
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Prescription Type
- 8.6.4 Market Breakup by Therapeutic Category
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Prescription Type
- 8.7.4 Market Breakup by Therapeutic Category
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Prescription Type
- 8.8.4 Market Breakup by Therapeutic Category
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Pharmaceutical Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Pharmaceutical Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis